Home » News » 01/06 » Organon collaborates with UK research firm

Organon collaborates with UK research firm

Date published: 26/01/2006

Organon, the healthcare business of Akzo Nobel, is to go into a collaborative research agreement with UK firm Sareum Holdings. The aim of the agreement is to develop new therapies for autoimmune diseases such as rheumatoid arthritis.

Sareum will determine the three-dimensional structures of two of the Organon autoimmune disease protein targets and then deploy its template screening method to identify new compounds suitable for drug development. Sareum chief executive Dr Tim Mitchell said: "We are delighted that Organon has chosen Sareum as their partner in drug lead identification and optimisation.

"This is the largest collaboration we have signed to date and brings together our expertise in protein structure determination, template screening and automated chemistry. We look forward to successfully identifying novel drug leads for this important therapeutic area." Although financial details have not been released Sareum will receive research fees and milestone payments.

© Adfero Ltd

Disclaimer

AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.